Key Takeaways:
The European Medicines Agency validated Pfizer and Valneva's Lyme disease vaccine application, moving the candidate toward a potential first-in-class European approval. The regulator will begin assessing the Marketing Authorization Application for PF-07307405, the companies' 6-valent outer surface protein A (OspA)-based shot.
"We believe vaccination has the potential to provide an important new layer of protection against this debilitating disease," Annaliesa Anderson, senior vice president and chief vaccines officer at Pfizer, said. "Lyme disease remains the most common vector-borne illness in Europe, affecting more than 100,000 people each year."
The filing rests on efficacy above 70 percent observed in the Phase 3 VALOR trial, which enrolled 9,437 participants aged 5 years and older across high-incidence sites in the U.S., Canada, and Europe. Subjects received four doses — at months 0, 2, and 5-9, plus a fourth one year later — and the vaccine was well tolerated with no safety concerns identified. The candidate covers the six most prevalent OspA serotypes expressed by Borrelia burgdorferi sensu lato species in North America and Europe.
No approved human vaccine for Lyme disease exists, and PF-07307405 is the furthest along in clinical development, with two pivotal Phase 3 trials completed. The U.S. Centers for Disease Control and Prevention estimates about 476,000 people in the U.S. are diagnosed and treated each year, while 132,000 cases are reported annually in Europe from countries with surveillance systems. Valneva's Thomas Lingelbach noted more than 200 million people live in Lyme disease risk areas in Europe.
The vaccine works by triggering antibodies against six Borrelia OspA serotypes; when a tick feeds on a vaccinated person, those antibodies bind to OspA inside the tick and block the bacterium from reaching the human host. Pfizer and Valneva entered a collaboration and license agreement in April 2020, with Pfizer holding exclusive rights to manufacture and commercialize the shot assuming regulatory success.
EMA validation is a milestone for Valneva, whose smaller market capitalization makes its shares more sensitive to pipeline news, while offering a modest catalyst for Pfizer. Approval would hand the partners a first-mover position in a market where the disease's geographic footprint is widening. Investors will watch for the EMA's Committee for Medicinal Products for Human Use opinion and any subsequent U.S. filing as the next catalysts.
This article is for informational purposes only and does not constitute investment advice.
